Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 28, 2014

GE Healthcare Life Sciences Licenses Mammalian Cell-Line Knowhow from Promosome

  • GE Healthcare Life Sciences inked a licensing agreement that gave it exclusive rights to a suite of mammalian cell-line development technologies developed by Promosome for increasing protein expression in mammalian cell culture. Promosome will receive milestone payments for technology transfer and subsequent royalties upon commercialization.

    “The biopharmaceutical industry is constantly looking for ways to improve efficiency and increase flexibility,” said Morgan Norris, general manager for upstream products, bioprocess, GE Healthcare Life Sciences. “Promosome’s technologies provide a powerful way to drive up protein yields and, more excitingly, boost the output of cell lines for hard-to-express proteins to a level where large-scale manufacturing becomes viable and previously disregarded therapies can be progressed.”

    GE Healthcare recently acquired Thermo Fisher’s HyClone™ cell culture media and sera. In 2012 the company launched KUBio™, an off-the-shelf modular factory for the manufacture of monoclonal antibodies.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »